GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide-copper chelate first isolated from human plasma in 1973 by Loren Pickart. It is present in plasma, saliva, and urine, with plasma concentrations declining measurably with age — from approximately 200 ng/mL at age 20 to around 80 ng/mL by age 60. This age-associated decline has sustained research interest across longevity, skin biology, wound healing, and neurological research. Researchers looking to source GHK-Cu for laboratory use can view our GHK-Cu research compound or browse the full peptide encyclopedia for further compound profiles.
Molecular Profile
GHK-Cu is a tripeptide composed of glycine, L-histidine, and L-lysine, coordinated with a copper(II) ion. It is assigned the CAS number 49557-75-7 and has a molecular formula of C14H24CuN6O4, with a molecular weight of approximately 403.9 Da. The histidine residue plays a central structural role in copper coordination, and the resulting complex demonstrates significantly greater biological activity than the free tripeptide alone. GHK-Cu is soluble in aqueous media and is typically supplied as a lyophilised powder for research use.
Proposed Mechanisms of Action
Preclinical research has identified several pathways through which GHK-Cu may exert its observed effects in cell culture and animal models. These include:
Gene Expression Modulation
One of the most thoroughly characterised properties of GHK-Cu is its capacity to modulate gene expression across a wide range of biological contexts. Research utilising the Broad Institute Connectivity Map established that GHK-Cu influences the expression of a substantial number of human genes. A 2014 analysis by Pickart et al. catalogued effects on genes involved in inflammation, DNA repair, antioxidant defence, and extracellular matrix organisation. More recent transcriptomic studies in fibroblasts have refined this picture, reporting upregulation of antioxidant genes including superoxide dismutase (SOD), suppression of matrix metalloproteinases MMP-1 and MMP-2, and apparent restoration of gene expression profiles associated with younger cellular states.
SIRT1/STAT3 Signalling Pathway
A 2025 study published in Frontiers in Pharmacology identified the SIRT1/STAT3 signalling axis as a primary molecular target of GHK-Cu activity. Using a dextran sulfate sodium (DSS)-induced murine model of ulcerative colitis, researchers demonstrated that GHK-Cu upregulated SIRT1 (NAD-dependent deacetylase sirtuin-1) protein expression while suppressing phosphorylated STAT3 (p-STAT3). Downstream effects included enhanced tight junction protein expression — specifically ZO-1 and Occludin — and reduced pro-inflammatory cytokines including IL-6, IL-1β, and TNF-α. Molecular docking analysis indicated direct binding between GHK-Cu and SIRT1 with a binding energy of -8.75 kcal/mol, suggesting a specific rather than non-specific interaction. SIRT1 is of broader significance in longevity research, with established roles in cellular metabolism, stress response, and inflammatory regulation.
Extracellular Matrix and Collagen Regulation
A substantial body of in vitro research has examined GHK-Cu’s effects on extracellular matrix (ECM) remodelling. Studies have reported upregulation of collagen synthesis alongside coordinated suppression of matrix metalloproteinases involved in ECM degradation — an effect pattern consistent with pro-regenerative activity in wound healing models. Research by Maquart et al. (1993) reported stimulation of collagen synthesis in fibroblast cultures, providing foundational evidence for GHK-Cu’s effects on connective tissue biology. Subsequent work has implicated transforming growth factor-beta (TGF-β) signalling as a downstream mediator of these ECM effects.
Anti-Inflammatory and Antioxidant Activity
Multiple preclinical studies have reported anti-inflammatory effects of GHK-Cu across different tissue and disease models. The compound appears to modulate NF-κB signalling and reduce production of pro-inflammatory cytokines in both cell culture and rodent models. In parallel, GHK-Cu has been associated with upregulation of endogenous antioxidant enzymes including superoxide dismutase and catalase. A review by Pickart and Margolina (2018) summarised the compound’s broad anti-inflammatory and antioxidant properties across the existing literature, contextualising them within a general framework of cellular reset and stress resistance.
Current Research Landscape
GHK-Cu has been investigated across multiple research domains, with preclinical work spanning wound healing, skin biology, hair follicle biology, neurological disease models, and longevity research. The existing literature is more diverse in terms of research groups than some other research peptides, with studies from independent laboratories in the US, Europe, and Asia.
Skin and Wound Healing Research
The most extensively studied application of GHK-Cu is in skin biology and wound repair. In vitro studies have reported stimulation of collagen and glycosaminoglycan synthesis, modulation of MMP activity, and promotion of fibroblast migration and proliferation. A series of studies by Maquart and colleagues in the 1990s established the foundation for GHK-Cu’s role in ECM biology, and subsequent research has continued to characterise its effects on dermal fibroblasts at the molecular level. More recent transcriptomic analysis has reported apparent reversal of age-associated gene expression changes in fibroblast models, an observation that has attracted attention in the context of longevity research.
Hair Follicle Biology
Research into GHK-Cu’s effects on hair follicle biology has identified interactions with the Wnt/β-catenin signalling pathway, a well-established regulator of hair follicle cycling. A 2024 study in ex vivo follicles reported upregulation of β-catenin by approximately 40% following GHK-Cu treatment, providing a more specific mechanistic basis for the hair-related effects observed in earlier research. Additional in vitro work has examined GHK-Cu’s effects on dermal papilla cell proliferation and survival, with reports of upregulated growth factor expression relevant to follicle maintenance.
Neurological Research
A more recent area of investigation involves GHK-Cu’s potential neuroprotective properties. A preclinical study using 5xFAD transgenic mice — a model of familial Alzheimer’s disease — administered GHK-Cu intranasally at 15 mg/kg three times per week over a three-month period. Researchers reported delayed cognitive impairment, reduced amyloid plaque burden in the frontal cortex and hippocampus, and decreased MCP1-mediated neuroinflammation. The translational gap between this murine model and human neurological disease remains substantial, and these findings should be interpreted with appropriate caution. Nonetheless, the study represents a notable expansion of the research contexts in which GHK-Cu is being investigated, consistent with the compound’s established anti-inflammatory and gene expression-modulating properties.
Topical versus Subcutaneous Research
A recurring methodological consideration in GHK-Cu research is the delivery route and the associated bioavailability challenge. The compound’s susceptibility to proteolytic degradation and limited skin penetration at biologically relevant concentrations have historically constrained in vivo study design. Published research has employed both topical and subcutaneous administration routes in preclinical models, with different formulations producing meaningfully different bioavailability profiles. Recent research has investigated novel delivery systems including ionic liquid microemulsions, liposomal encapsulation, and sustained-release hydroxyapatite formulations — with the hydroxyapatite-based approach demonstrating sustained release profiles extending over seven days in experimental models. These delivery system developments are relevant to the design of future in vivo studies requiring maintained compound exposure over extended periods. Researchers working with GHK-Cu should carefully consider administration route when designing experimental protocols and interpreting results from the existing literature.
As of the current date, GHK-Cu has not been the subject of large-scale randomised controlled trials in the peer-reviewed literature for any indication, and its mechanisms of action in human subjects remain to be established through controlled clinical research. For related compounds in longevity and tissue repair research, researchers may also wish to explore our articles on Epithalon and BPC-157, or browse our full Growth Factors and research compound catalogue.
Key Takeaways
- GHK-Cu is a naturally occurring tripeptide-copper complex with plasma concentrations that decline significantly with age, sustaining research interest across longevity and regenerative biology.
- The compound modulates expression of a large number of human genes, with recent transcriptomic research identifying SIRT1 and STAT3 as primary mechanistic targets.
- A 2025 Frontiers in Pharmacology study confirmed direct binding of GHK-Cu to SIRT1 (binding energy -8.75 kcal/mol) and downstream suppression of p-STAT3 and pro-inflammatory cytokines in a murine colitis model.
- Preclinical research spans wound healing, skin biology, hair follicle biology, and neurological disease models, with studies from multiple independent research groups.
- Delivery route significantly affects bioavailability; novel formulations including ionic liquid microemulsions and hydroxyapatite systems are an active area of investigation.
- The evidence base remains predominantly preclinical — large-scale randomised controlled trials in human subjects are not yet available in the peer-reviewed literature.
Frequently Asked Questions
What does GHK stand for?
GHK stands for glycyl-L-histidyl-L-lysine, the three amino acids that form the tripeptide backbone of the compound. The “Cu” designation refers to the copper(II) ion coordinated with the peptide, which is essential for its observed biological activity. The free tripeptide GHK without copper coordination shows markedly reduced activity in most research models.
Is GHK-Cu naturally occurring?
Yes. GHK-Cu is a naturally occurring compound found in human plasma, saliva, and urine. It was first isolated from human plasma by Loren Pickart in 1973. Plasma concentrations are measurably higher in younger individuals and decline with age, which has made it a subject of interest in longevity and anti-ageing research contexts. For further background, see our peptide encyclopedia entry on GHK-Cu.
What research models have been used to study GHK-Cu?
GHK-Cu has been studied across a range of research models including primary human fibroblast cultures, keratinocyte cell lines, ex vivo hair follicle preparations, and rodent in vivo models. Administration routes in preclinical research include topical, subcutaneous, and intranasal delivery. The compound has also been extensively studied in transcriptomic analyses using datasets from the Broad Institute Connectivity Map. For a broader overview of research peptide categories, visit our research hub.
How does GHK-Cu differ from other copper peptides used in research?
GHK-Cu is the most extensively studied copper peptide in the academic literature. Other copper peptides used in cosmetic and research contexts include AHK-Cu (alanyl-histidyl-lysine copper) and GHK alone, but neither has the breadth of published preclinical data available for GHK-Cu. The specific tripeptide sequence and copper coordination geometry of GHK-Cu appear to be important determinants of its biological activity, as modifications to the peptide sequence generally reduce potency in standard in vitro assays.
This content is intended for researchers and scientific professionals only. All compounds referenced are for laboratory research use exclusively. Nothing in this article constitutes medical advice or implies suitability for human use.
